Peptides Similar to Tesofensine
Compare Tesofensine with related peptides and alternatives
📌TL;DR
- •5 similar peptides identified
- •Semaglutide: Both are investigated for chronic weight management in adults with obesity, and both reduce appetite to drive negative energy balance.
- •Tirzepatide: Both target obesity; both have shown substantial weight loss in Phase 2 / Phase 3 clinical research.
Comparison chart of Tesofensine and similar peptides
Infographic pending generation
Quick Comparison
| Peptide | Similarity | Key Differences |
|---|---|---|
| Tesofensine (current) | - | - |
| Semaglutide | Both are investigated for chronic weight management in adults with obesity, and both reduce appetite to drive negative energy balance. | Semaglutide is a GLP-1 receptor agonist peptide given by weekly subcutaneous injection; tesofensine is a small-molecule oral monoamine reuptake inhibitor (SNDRI). Semaglutide is FDA-approved (Wegovy, Ozempic, Rybelsus); tesofensine is not. Semaglutide's side-effect profile is dominated by GI events, tesofensine's by sympathomimetic and CNS effects. |
| Tirzepatide | Both target obesity; both have shown substantial weight loss in Phase 2 / Phase 3 clinical research. | Tirzepatide is a dual GIP/GLP-1 receptor agonist peptide given by weekly subcutaneous injection and is FDA-approved (Mounjaro, Zepbound). Tesofensine is an oral small-molecule SNDRI and is not approved. Tirzepatide's Phase 3 weight loss exceeds tesofensine's Phase 2 weight loss in magnitude and trial duration. |
| Retatrutide | Both are investigational obesity drugs targeting central / metabolic pathways that drive appetite and energy expenditure. | Retatrutide is an investigational triple GIP / GLP-1 / glucagon receptor agonist peptide given by weekly subcutaneous injection, with the highest weight-loss magnitude reported in any Phase 3 obesity trial to date (approximately 28.7% at 68 weeks in TRIUMPH-4). Tesofensine is an oral small molecule with approximately 12.8% Phase 2 weight loss at 24 weeks. |
| Mazdutide | Both are investigational anti-obesity therapies in late-stage development. | Mazdutide is a dual GLP-1 / glucagon receptor agonist peptide (injection); tesofensine is an oral small-molecule SNDRI. Different mechanisms entirely. |
| Cagrilintide | Both target appetite reduction in obesity through central nervous system mechanisms - cagrilintide via the amylin pathway and tesofensine via monoamine reuptake. | Cagrilintide is an amylin analogue peptide given by weekly injection, typically studied as monotherapy or in combination with semaglutide (CagriSema). Tesofensine is an oral small molecule with completely different pharmacology. |
SemaglutideBoth are investigated for chronic weight management in adults with obesity, and both reduce appetite to drive negative energy balance.
Differences
Semaglutide is a GLP-1 receptor agonist peptide given by weekly subcutaneous injection; tesofensine is a small-molecule oral monoamine reuptake inhibitor (SNDRI). Semaglutide is FDA-approved (Wegovy, Ozempic, Rybelsus); tesofensine is not. Semaglutide's side-effect profile is dominated by GI events, tesofensine's by sympathomimetic and CNS effects.
Advantages
Once-daily oral administration (no injection); mechanism is non-overlapping with GLP-1 RAs, raising theoretical (untested) combination potential.
Disadvantages
Not FDA-approved; smaller and older evidence base; heart-rate and mood/sleep adverse events; serotonergic drug-interaction risk.
TirzepatideBoth target obesity; both have shown substantial weight loss in Phase 2 / Phase 3 clinical research.
Differences
Tirzepatide is a dual GIP/GLP-1 receptor agonist peptide given by weekly subcutaneous injection and is FDA-approved (Mounjaro, Zepbound). Tesofensine is an oral small-molecule SNDRI and is not approved. Tirzepatide's Phase 3 weight loss exceeds tesofensine's Phase 2 weight loss in magnitude and trial duration.
Advantages
Oral administration; non-incretin mechanism may suit patients intolerant of GLP-1 RA GI effects.
Disadvantages
Inferior published evidence base; cardiovascular and CNS adverse events; no FDA approval.
RetatrutideBoth are investigational obesity drugs targeting central / metabolic pathways that drive appetite and energy expenditure.
Differences
Retatrutide is an investigational triple GIP / GLP-1 / glucagon receptor agonist peptide given by weekly subcutaneous injection, with the highest weight-loss magnitude reported in any Phase 3 obesity trial to date (approximately 28.7% at 68 weeks in TRIUMPH-4). Tesofensine is an oral small molecule with approximately 12.8% Phase 2 weight loss at 24 weeks.
Advantages
Oral, mechanistically independent of incretin biology.
Disadvantages
Substantially smaller weight-loss magnitude than retatrutide; older and smaller evidence base.
MazdutideBoth are investigational anti-obesity therapies in late-stage development.
Differences
Mazdutide is a dual GLP-1 / glucagon receptor agonist peptide (injection); tesofensine is an oral small-molecule SNDRI. Different mechanisms entirely.
Advantages
Oral administration; mechanism does not overlap with mazdutide.
Disadvantages
Smaller evidence base than incretin / glucagon agonist programs.
CagrilintideBoth target appetite reduction in obesity through central nervous system mechanisms - cagrilintide via the amylin pathway and tesofensine via monoamine reuptake.
Differences
Cagrilintide is an amylin analogue peptide given by weekly injection, typically studied as monotherapy or in combination with semaglutide (CagriSema). Tesofensine is an oral small molecule with completely different pharmacology.
Advantages
Oral route; no overlap with amylin biology.
Disadvantages
No combination data with amylin analogues; less mature obesity evidence.
Similarities and differences between Tesofensine and related peptides
Infographic pending generation
Tesofensine vs Peptide Obesity Drugs: Comparison#
Tesofensine occupies an unusual position in the obesity drug landscape: it shares the indication of modern peptide GLP-1 / GIP / glucagon agonists (semaglutide, tirzepatide, retatrutide, mazdutide) but has an entirely different mechanism (central monoamine reuptake inhibition rather than peripheral incretin / amylin biology), an entirely different route (oral vs injection), and a substantially smaller and older evidence base. This page collects the practical comparisons.
Overview: Different Mechanism, Same Indication#
| Drug | Class | Mechanism | Route | Approval status |
|---|---|---|---|---|
| Tesofensine | Small molecule (phenyltropane) | SNDRI (SERT + NET + DAT) | Oral daily | Not FDA-approved (June 2026) |
| Semaglutide | Peptide | GLP-1 receptor agonist | SC weekly (or oral Rybelsus) | FDA-approved |
| Tirzepatide | Peptide | Dual GIP / GLP-1 agonist | SC weekly | FDA-approved |
| Retatrutide | Peptide | Triple GIP / GLP-1 / glucagon agonist | SC weekly | Investigational (Phase 3) |
| Mazdutide | Peptide | Dual GLP-1 / glucagon agonist | SC weekly | Investigational |
| Cagrilintide | Peptide | Amylin analogue | SC weekly | Investigational |
Detailed Comparisons#
Tesofensine vs Semaglutide#
Both target appetite to drive weight loss, but the mechanism differs entirely. Semaglutide (STEP 1; Wilding JPH et al., NEJM 2021; PMID 33567185) produced approximately 14.9% mean body weight loss at 68 weeks. Tesofensine (Astrup A et al., Lancet 2008; PMID 18950853) produced approximately 12.8% mean total body weight loss at 24 weeks at the 1.0 mg dose. Semaglutide has substantially more long-term, multi-site, peer-reviewed evidence; tesofensine has neither FDA approval nor a published Phase 3 outcomes trial.
Tesofensine vs Tirzepatide#
Tirzepatide is FDA-approved (Mounjaro for type 2 diabetes; Zepbound for obesity) and demonstrated approximately 20.9% weight loss at 72 weeks in SURMOUNT-1. Tesofensine has not been compared head-to-head and lacks any Phase 3 evidence base of comparable scale.
Tesofensine vs Retatrutide#
Retatrutide is the current Phase 3 weight-loss leader at approximately 28.7% at 68 weeks (TRIUMPH-4; Giblin K et al., Diabetes Obesity & Metabolism 2026; PMID 41090431). Tesofensine's Phase 2 24-week reading of approximately 12.8% is materially smaller, although the two compounds have not been studied in a directly comparable trial.
Tesofensine vs Phentermine and Sibutramine#
The closest historical small-molecule comparators are:
- Phentermine - an FDA-approved noradrenergic anti-obesity drug for short-term use; produces approximately 5-10% weight loss over 3-12 months in pivotal data. Tesofensine has broader monoamine activity (adds serotonergic and dopaminergic effects).
- Sibutramine - an SNRI (serotonin and noradrenaline reuptake inhibition) anti-obesity drug withdrawn from major markets in 2010 over cardiovascular safety concerns. The sibutramine experience informs both the cardiovascular monitoring approach for tesofensine and the rationale for the Tesomet combination with metoprolol.
Practical Differences#
- Route: Tesofensine is oral, daily. GLP-1 / GIP agonists are mostly weekly injections (Rybelsus is the daily oral GLP-1 alternative).
- Side-effect profile: Tesofensine is dominated by sympathomimetic (HR, BP), CNS (insomnia, mood), and serotonergic interaction concerns. GLP-1 agonists are dominated by GI events (nausea, vomiting, diarrhoea) with smaller cardiovascular signal.
- Cold-chain: Tesofensine is room-temperature stable; injectable GLP-1 agonists generally require refrigeration.
- Cost / access: Tesofensine has no legal US pharmacy supply chain. GLP-1 agonists are widely prescribed and (semaglutide and tirzepatide) compounded.
References#
Related Reading#
Frequently Asked Questions About Tesofensine
Is Tesofensine an alternative to Ozempic / Wegovy?
Mechanistically tesofensine is entirely different from semaglutide (Ozempic / Wegovy). Tesofensine is an oral small-molecule SNDRI; semaglutide is an injected GLP-1 agonist peptide. Tesofensine is also not FDA-approved, so it is not a regulatory or clinical alternative - it is an investigational research compound. People seeking an approved oral alternative to semaglutide should consider Rybelsus (oral semaglutide).
Can Tesofensine be combined with Semaglutide or Tirzepatide?
No clinical data support combining tesofensine with GLP-1 receptor agonists. Mechanistically the combination is non-overlapping, but cardiovascular and serotonergic risks would need careful evaluation before any combination trial. This combination has not been published.
How does Tesofensine compare to Phentermine?
Both are central nervous system appetite suppressants with noradrenergic activity, but phentermine is an FDA-approved sympathomimetic amine for short-term obesity treatment, while tesofensine is an investigational triple monoamine reuptake inhibitor with significant serotonergic and dopaminergic activity in addition to noradrenergic. Tesofensine's weight-loss magnitude in Phase 2 exceeded what is typically reported for phentermine monotherapy.
What is the closest mechanistic comparator to Tesofensine?
Mechanistically, sibutramine - the withdrawn serotonin-noradrenaline reuptake inhibitor (SNRI) anti-obesity drug - was the closest prior comparator, but it lacked tesofensine's dopaminergic activity. Sibutramine was withdrawn from major markets in 2010 over cardiovascular safety concerns, which informs the cardiovascular monitoring approach for tesofensine and the development of Tesomet (combination with metoprolol).
Explore Further
Disclaimer: For educational purposes only. Not medical advice. Read full disclaimer